BidaskClub upgraded shares of PRA Health Sciences (NASDAQ:PRAH) from a hold rating to a buy rating in a research report sent to investors on Thursday.

Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of PRA Health Sciences from a hold rating to a buy rating and set a $85.00 target price on the stock in a report on Wednesday, August 30th. SunTrust Banks restated a buy rating and issued a $101.00 target price on shares of PRA Health Sciences in a report on Friday, October 27th. Jefferies Group restated a buy rating and issued a $95.00 target price on shares of PRA Health Sciences in a report on Thursday, October 26th. Credit Suisse Group raised their target price on shares of PRA Health Sciences from $90.00 to $93.00 and gave the stock an outperform rating in a report on Thursday, October 26th. Finally, KeyCorp restated a buy rating and issued a $93.00 target price (up previously from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. PRA Health Sciences currently has an average rating of Buy and a consensus target price of $90.46.

Shares of PRA Health Sciences (PRAH) traded up $1.12 during mid-day trading on Thursday, reaching $90.25. 1,079,186 shares of the company traded hands, compared to its average volume of 483,123. PRA Health Sciences has a 52 week low of $53.47 and a 52 week high of $90.43. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $5,719.14, a PE ratio of 33.18, a P/E/G ratio of 1.56 and a beta of 0.40.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The company had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. During the same quarter last year, the company posted $0.64 earnings per share. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. analysts predict that PRA Health Sciences will post 3.2 EPS for the current year.

In related news, Director Matthew P. Young sold 5,115 shares of PRA Health Sciences stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 2.10% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio lifted its stake in shares of PRA Health Sciences by 2,857.2% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 5,944 shares of the medical research company’s stock valued at $453,000 after buying an additional 5,743 shares in the last quarter. Salem Investment Counselors Inc. bought a new stake in PRA Health Sciences in the 3rd quarter valued at $315,000. Ameritas Investment Partners Inc. increased its holdings in PRA Health Sciences by 23.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 4,204 shares of the medical research company’s stock valued at $325,000 after acquiring an additional 800 shares during the last quarter. Neuberger Berman Group LLC increased its holdings in PRA Health Sciences by 2,738.6% in the 3rd quarter. Neuberger Berman Group LLC now owns 245,711 shares of the medical research company’s stock valued at $18,716,000 after acquiring an additional 237,055 shares during the last quarter. Finally, South Street Advisors LLC increased its holdings in PRA Health Sciences by 1.2% in the 3rd quarter. South Street Advisors LLC now owns 109,595 shares of the medical research company’s stock valued at $8,347,000 after acquiring an additional 1,250 shares during the last quarter. Institutional investors own 98.49% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “PRA Health Sciences (PRAH) Upgraded at BidaskClub” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/17/pra-health-sciences-prah-upgraded-at-bidaskclub.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Stock Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related stocks with our FREE daily email newsletter.